Health Condition 1: F209- Schizophrenia, unspecified
Conditions
Interventions
Intervention1: Alpha lipoic acid: Alpha lipoic acid Administration of ALA 300 mg oral once daily for 3 months as an adjunct to antipsychotic medication
Control Intervention1: Placebo: Placebo once dai
Sponsors
Dr Ramya R
Eligibility
Inclusion criteria
Inclusion criteria: 1)Schizophrenia diagnosis made by research psychiatrists using the Structured Clinical Interview, SCID-5, for Diagnostic and Statistical Manual of Mental Disorders of more than 2 years duration and on treatment 2)Cognitive symptoms despite adequate antipsychotic treatment assessed by MOCA scored 3)Age 18-60 years of either gender 4)Willing to participate
Exclusion criteria
Exclusion criteria: 1)6-months history of any drug or alcohol abuse or dependence 2)Changes in psychotropic medications within the last 4 weeks and patients on valproate use (potential interaction with ALA) 3)Women who are planning to become pregnant, are pregnant, or are breastfeeding 4)Known chronic infections such as HIV or hepatitis C, and liver or renal failure that could adversely impact on patient outcome
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1) Effect of alpha lipoic acid on executive functioning-attention, inhibition, working memory, Orientation through Montreal Cognition Assessment scaleTimepoint: Baseline to 12 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| 1)Effect of alpha lipoic acid on improving cognition and disability 2) Effect of alpha lipoic acid on quality of lifeTimepoint: Baseline to 12 weeks | — |
Countries
India
Contacts
Public ContactDr V Sathyanarayanan
SRM medical college
Outcome results
None listed